Cabiralizumab
- Generic Name
- Cabiralizumab
- Drug Type
- Biotech
- CAS Number
- 1613144-80-1
- Unique Ingredient Identifier
- 5FJL6W0640
- Background
Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
Advancements in Tenosynovial Giant Cell Tumors Clinical Trials Highlighted for 2024
The Tenosynovial Giant Cell Tumors (TGCT) clinical trials landscape for 2024 showcases significant progress, with over 5 key companies developing more than 5 treatment therapies. Notable developments include the FDA's priority review for vimseltinib, a CSF1R inhibitor, and the EMA's acceptance of its Marketing Authorization Application, signaling a promising future for TGCT treatment.
Tenosynovial Giant Cell Tumors Treatment Market to See Significant Growth by 2034
The Tenosynovial Giant Cell Tumors (TSGCTs) treatment market, valued at approximately USD 300 million in 2023, is expected to grow significantly by 2034. This growth is driven by the increasing prevalence of TSGCTs, advancements in treatment options, and the introduction of novel therapies. Key developments include SynOx Therapeutics securing USD 75 million in Series B funding for the development of emactuzumab, a promising treatment for TSGCTs.
Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment
• Combining anti-PD-(L)1 antibodies with hyaluronidase enhances tumor growth inhibition by remodeling the stroma and improving drug delivery in pancreatic cancer models.
• Blocking IL-6 in combination with anti-PD-L1 antibodies inhibits tumor volume and increases survival in preclinical pancreatic cancer models, warranting clinical verification.
• Combining CD40 agonists with PD-L1 blockade improves overall survival and promotes anti-tumor immunity in orthotopic pancreatic cancer mouse models.
• Inhibiting the CXCL12/CXCR4 pathway alongside anti-PD-(L)1 therapy modulates immunosuppression and demonstrates synergistic effects in treating pancreatic cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath